Search
Hepatitis B immune globulin
go.drugbank.com/drugs/DB05276ApprovedInvestigationalInfection with hepatitis B may lead to hepatocellular carcinoma, a type of liver cancer. Therefore, the hepatitis-B vaccines are cancer-preventing vaccines.
Products: HEPATECT®CP 500 UI (INMUNOGLOBULINA HUMANA CONTRA EL VIRUS DE LA HEPATITIS B)., HEPATECT ® CP 2000 U.IX 40ML (INMUNOGLOBULINAHUMANAHIPERINMUNECONTRA EL VIRUS DE LA HEPATITIS B)SPP 301
go.drugbank.com/drugs/DB05290InvestigationalSPP301 (Avosentan) is a potent and highly selective ET[A] receptor blocker and is clinically investigated in diabetic nephropathy.
IDM-2
go.drugbank.com/drugs/DB05293ExperimentalIDM-2 is composed of Monocyte-derived Activated Killer (MAK) cells. IDM produces MAK cells from the patient's own white blood cells by activating these cells ex vivo to allow them to recognize and destroy tumor cells.
Rusalatide
go.drugbank.com/drugs/DB05309InvestigationalTP508 is a non-proteolytic synthetic peptide representing the portion of human thrombin originally identified as the fibroblast high-affinity receptor binding domain.
Oportuzumab monatox
go.drugbank.com/drugs/DB05319Investigationaland a truncated portion of Pseudomonas exotoxin A. … VB4-845 is made by linking a monoclonal antibody fragment to a toxic protein that may kill cancer cells.
VGV-1
go.drugbank.com/drugs/DB05328ExperimentalVGV-1 is a potential salvage therapy for treatment of HIV infected people who have failed anti-retroviral therapy.
ALTU-135
go.drugbank.com/drugs/DB05330InvestigationalALTU-135, the Company's orally administered enzyme replacement therapy for patients with pancreatic insufficiency, is manufactured by blending three drug substance enzymes: lipase, protease and amylase. This consistent and pure enzyme co...
Arundic acid
go.drugbank.com/drugs/DB05343InvestigationalArundic acid has been investigated for the treatment of Amyotrophic Lateral Sclerosis (ALS).
ACR-16
go.drugbank.com/drugs/DB05371InvestigationalACR-16 is a dopamine stabilizer. ACR-16 is also being studied in other psychiatric and neurologic diseases. … ACR16 has been successfully investigated in a Phase II multi-centre, randomised and placebo-controlled trial in patients with Huntington’s disease as well as in three Phase Ib studies within Huntington
AZD 3355
go.drugbank.com/drugs/DB05404InvestigationalAZD 3355 is a reflux inhibitor used for the treatment of Gastroesophageal Reflux Disease. It is developed by AstraZeneca and is currently in phase I/II trials.
Categories: GABA-A Receptor Agonists